KITLG and neoplasm: The differential tumor versus normal expression of KIT and of its ligand KITLG was identified as being the major driver of the correlation with the PFS of the patients treated with axitinib (Supplemental Fig. 1a, b), and their combined vector KIT-KITLG generated the optimal performance in the correlation with PFS: r = 0.99, p = 4.68E−04 (Supplemental Fig. 1c).